Consensus Avalo Therapeutics, Inc.

Stocks

AVTX

US05338F3064

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-29 EDT			5-day change	1st Jan Change
15.58 ^USD	+3.32%		-5.63%	-14.21%

09-20	Avalo Therapeutics, Inc.(NasdaqCM:AVTX) added to S&P Global BMI Index	CI
08-19	Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing	MT

Evolution of the Average Target: Avalo Therapeutics, Inc.

Evolution of the Target Price: Avalo Therapeutics, Inc.

Changes in Analyst Recommendations: Avalo Therapeutics, Inc.

3be78086c82c13.rdJEVoWF-2YW_vfKs7P2ia-j9t5fbL7MLyVF3Zh3g08.nbk0FLfpvQx6yLWlwt-5z-bKnewmII_6RQgduOtCyiXYtCs-sdy5LSa0mA~69a20f393bf09ff7d114fc44e78c2e5c

Analysts' recommendations: Avalo Therapeutics, Inc.

06-12	Avalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says	MT
06-12	BofA Initiates Avalo Therapeutics at Buy With $35 Price Target	MT
05-14	Mizuho Adjusts Price Target on Avalo Therapeutics to $45 From $39, Maintains Outperform Rating	MT
05-14	Wedbush Adjusts Price Target on Avalo Therapeutics to $34 From $40, Maintains Outperform Rating	MT
05-06	Wedbush Adjusts Price Target on Avalo Therapeutics to $40 From $29, Maintains Outperform Rating	MT
03-24	Wedbush Raises Price Target on Avalo Therapeutics to $29 From $28, Keeps Outperform Rating	MT
02-02	Guggenheim Initiates Coverage on Avalo Therapeutics With Buy Rating, $50 Price Target	MT
12-18	Mizuho Initiates Avalo Therapeutics at Outperform With $39 Price Target	MT
25-09-05	TD Cowen Initiates Avalo Therapeutics at Buy	MT
25-08-15	Cantor Fitzgerald Initiates Avalo Therapeutics at Overweight	MT
25-03-25	Stifel Initiates Avalo Therapeutics at Buy With $36 Price Target	MT
25-02-28	Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target	MT
25-02-21	Wedbush Initiates Avalo Therapeutics With Outperform Rating, $18 Price Target	MT
24-12-19	BTIG Research Initiates Avalo Therapeutics With Buy Rating, $40 Price Target	MT
24-10-24	HC Wainwright Initiates Avalo Therapeutics at Neutral	MT
24-04-16	Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	MT
23-06-27	Oppenheimer Downgrades Avalo Therapeutics to Perform From Outperform, Removes $10 Price Target	MT
23-06-27	Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept	MT
23-05-10	RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier	MT
23-02-08	Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50	MT
22-11-09	Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating	MT
22-08-08	Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating	MT
22-08-05	RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier	MT
22-07-11	RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept	MT
22-05-06	RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk With Minimal Safeguards,' Keeps Outperform-Speculative Risk Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AVALO THERAPEUTICS, INC.					+192.33%
	WUXI APPTEC CO., LTD.					+15.62%
	ARGENX SE					+22.39%
	WUXI BIOLOGICS (CAYMAN) INC.					+9.04%
	INSMED INCORPORATED					+69.15%
	BIONTECH SE					+18.27%
	GENMAB A/S					+6.59%
	PHARMAESSENTIA CORPORATION					+20.98%
	EXELIXIS, INC.					-8.02%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+36.13%
	Average					+38.25%
	Weighted average by Cap.					+21.58%